Clinical Trial Search

Primary: Change From Baseline in Insulin Sensitivity — -1.91; -5.63 min ^ -1 / mIU / L

Primary: Pregnancy Rate (Expressed as Pearl Index) for Women 18 to 45 Years Old, MITT Population — 1.823; 2.978 Pearl Index

Primary: Pregnancy Rate (Expressed as Pearl Index) in Women Aged 18 to 35, MITT Population, — 2.554 Pregnancy Rate

Primary: Changes in Insulin Sensitivity Associated With Oral Contraceptive (OC) Use Compared Among (1) Obese Women and (2) Lean Women — 4.36; 6.62; 3.82; 8.23 mIU/L

Primary: Pearl Index, 18-35 Years, MITT Population — 1.903 Pearl Index

Primary: Cmax of Norethindrone — 10.94; 10.00 ng/mL

Primary: Annualized Pregnancy Rate (Pearl Index) For 91-Day Cycles by Cohort Using up to 14 Days Post-Last Combination Dose When Defining "On Drug" Pregnancy — 2.44; 2.42; 1.77…

Primary: Efficacy: the Pearl Index (Number of Pregnancies Per 100 Woman-years) in the Primary Evaluable Population (18-35) — 22.4 pregnancies per 100 woman years

Primary: Cmax of Norethindrone — 4.3306; 4.2282 ng/mL

Primary: LNG Steady State at Baseline and Then Post-randomization — 3.82; 3.13; 3.01; 3.58 ng/mL

Primary: Pre-Post Change in Premenstrual Symptom Severity — 1.93; 1.73; 1.64 units on a scale

Primary: Follicle-stimulating Hormone — 5.01; 5.86; 6.38 milli international units per milliliter — p=0.88

Primary: Number of Participants Who Continued to Breastfeed at 6 Months — 15; 14; 8; 9 participants

Primary: Breast Cell Proliferation Levels Between the Two Oral Contraceptive Dose Groups — 7.5; 12.4 Percent of cells staining for Ki67

Primary: Changes in Insulin-like Growth Factor-1 (IGF-1), IGF Binding Proteins (IGFBP-1, IGFBP-3), and Acid Labile Subunit (ALS) — 220.6; 228.7; 197.1; 221.4 ng/mL

Primary: Breast Cell Proliferation Levels Between the Three Oral Contraceptive Groups — 8.5; 11.9; 7.5 Percent of cells staining for Ki67

Primary: Number of Premenopausal Women With Overweight/Obesity Who Initiated a COC vs. Continued NHC Use, Enrolled and Remained in This Study, and Completed Outcome Measures — 9…

Primary: Differences in Bleeding Patterns Between Study Groups. — 26.72; 31.86; 25.69; 18.84 days

Primary: Continuation Rates — 82; 78; 83 participants

Primary: The Change in Average of the 3 Highest Visual Analog Scale (VAS) Values of the Hormone Withdrawal-associated Symptoms Pelvic Pain or Headache During Cycle Days 22 to 28…

Primary: Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression. — 54; 28; 11; 12 Participants

Primary: All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 28-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight, Using the 7-Day Rule…

Primary: Change in Visual Analog Scale (VAS) Score — -74.8; -58.7 units on a scale — p=0.05

Primary: Thickness of the Vaginal Epithelium (in mm)With Means and Standard Deviations Reported. — 0.01; -0.005; -0.02; .007 mm

Primary: Red Blood Cell (RBC) Folate Level at 24 Weeks — 1406.91; 1022.21 nmol/L — p=<0.0001

Primary: All Users Pregnancy Rates Based on Pearl Index (PI) Analyses for 91-Day Cycles and Broken Out by Subpopulations Defined by Participant Weight — 2.82; 2.46; 4.54…

Primary: Number of Participants Choosing Each Hormonal Contraceptive Method Before and After Counseling — 1207; 1199; 60; 131 Participants — p=0.705

Primary: Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing Interval at Steady State (AUC [0-tau]) of EE — 748.7 Hour*picograms per…

Primary: Area Under the Concentration Versus Time Curve for 0 to 24 Hours After Drug Administration, Done Between Days 9 and 12 of the Menstrual Cycle at Time 1 (Before) and Time…

Primary: Matsuda Index- Whole Body Insulin Sensitivity Index — -1.02; -0.10; -1.45 units on a scale — p=0.27